1. Home
  2. ARTL vs CHEK Comparison

ARTL vs CHEK Comparison

Compare ARTL & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • CHEK
  • Stock Information
  • Founded
  • ARTL 2011
  • CHEK 2004
  • Country
  • ARTL United States
  • CHEK Israel
  • Employees
  • ARTL N/A
  • CHEK 85
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • CHEK Medical Electronics
  • Sector
  • ARTL Health Care
  • CHEK Health Care
  • Exchange
  • ARTL Nasdaq
  • CHEK Nasdaq
  • Market Cap
  • ARTL 3.6M
  • CHEK 4.0M
  • IPO Year
  • ARTL N/A
  • CHEK 2015
  • Fundamental
  • Price
  • ARTL $0.95
  • CHEK $0.67
  • Analyst Decision
  • ARTL Strong Buy
  • CHEK
  • Analyst Count
  • ARTL 2
  • CHEK 0
  • Target Price
  • ARTL $5.50
  • CHEK N/A
  • AVG Volume (30 Days)
  • ARTL 1.2M
  • CHEK 27.9K
  • Earning Date
  • ARTL 05-12-2025
  • CHEK 05-14-2025
  • Dividend Yield
  • ARTL N/A
  • CHEK N/A
  • EPS Growth
  • ARTL N/A
  • CHEK N/A
  • EPS
  • ARTL N/A
  • CHEK N/A
  • Revenue
  • ARTL N/A
  • CHEK N/A
  • Revenue This Year
  • ARTL N/A
  • CHEK N/A
  • Revenue Next Year
  • ARTL N/A
  • CHEK N/A
  • P/E Ratio
  • ARTL N/A
  • CHEK N/A
  • Revenue Growth
  • ARTL N/A
  • CHEK N/A
  • 52 Week Low
  • ARTL $0.82
  • CHEK $0.56
  • 52 Week High
  • ARTL $1.59
  • CHEK $3.04
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 50.27
  • CHEK 40.14
  • Support Level
  • ARTL $0.82
  • CHEK $0.65
  • Resistance Level
  • ARTL $1.40
  • CHEK $0.73
  • Average True Range (ATR)
  • ARTL 0.11
  • CHEK 0.06
  • MACD
  • ARTL 0.02
  • CHEK -0.00
  • Stochastic Oscillator
  • ARTL 23.10
  • CHEK 25.00

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: